What did Infratil Limited announce?

Infratil Limited (NZX: IFT) filed “CDC Independent Valuation – 30 September 2026” with NZX on 6 October 2026, as a market update announcement.

When was it filed?
6 October 2026
Where is the original?
NZX announcement
Infratil Limited/Announcement
Infratil Limited logo

CDC Independent Valuation – 30 September 2026

Market Update6 October 2026IFTUtilities

Infratil Limited 5 Market Lane, PO Box 320, Wellington, New Zealand Tel +64-4-473 3663 www.infratil.com
7 October 2026

CDC Independent Valuation – 30 September 2026


CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30

September 2026. Continued progress in customer contracting and the development of CDC’s

capacity pipeline was offset by the macroeconomic impact of a material increase in the forward

yield curve, resulting in higher assumed interest costs over the forecast period.


The valuation decreased by A$78 million from 30 June 2026 to A$18.45 billion, reflecting the

mid-point of the assessed valuation range of A$17.4 billion to A$19.6 billion. Infratil’s 49.69%

interest in CDC is valued at A$9,168 million, down A$45 million from A$9,213 million at 30 June

2026, which reflected Infratil’s interest of 49.72%.


Further valuation details are included in the attached presentation document.


Enquiries should be directed to:


Brett Jackson

Investor Relations

Email: brett.jackson@infratil.com


Authorised for release by:


Matthew Ross

Infratil Chief Financial Officer

---

CDC
INDEPENDENT

VALUATION


30 SEPTEMBER

2026

•CDC’s independent valuation was broadly flat with a mid-point valuation of A$18.5 billion at 30 September 2026.
•Continued progress in customer contracting and the development of CDC’s capacity pipeline was offset by the macroeconomic impactof a material

increase in the forward yield curve, resulting in higher assumed interest costs over the forecast period.

–The valuation decreased by A$78 million from 30 June 2026 to A$18.45 billion, reflecting the mid-point of the assessed valuationrange of

A$17.4 billion to A$19.6 billion.

–Infratil’s49.69% interest in CDC is valued at A$9,168 million, down A$45 million from A$9,213 million at 30 June 2026, which reflected Infratil’s

interest of 49.72%.

•The key drivers of the movement in the independent valuation this quarter were:

–Contracted capacity increased to 1.1 GW with a further 70 MW contracted, acceleration of the build programme at various locations, and a 240

MW increase in CDC’s total reported pipeline to 4.2 GW.

–These positive cash flow movements were offset by a material increase in the forward yield curve, which drove forecast debt servicing costs

within the cash flows, and resulted in higher assumed interest costs over the forecast period.

•The independent valuer assessed that the cost of equity increased from 12.45% to 12.58% during the quarter, driven by:

–An increase in the forecast long-term gearing ratio.

–The risk-free rate used in the discount rate is a long-term benchmark and was unchanged at 4.25%.

–This was partly offset by a minor decrease in the asset-specific risk premium associated with continued progress in constructionand

development activity.

•Net debt increased by A$1,161 million over the quarter. Separately, CDC raised A$1.7 billion in debt, including A$700 million in Australian Medium-

Term Notes and A$1 billion through a US Private Placement.

CDC Independent Valuation Update –30 September 2026

1

Valuation Methodology30 September 202630 June 2026
Primary valuation methodologyDCF using FCFE

(with a cross check to market multiples and precedent

transactions)

DCF using FCFE

(with a cross check to market multiples and precedent

transactions)

Terminal year20552055

Enterprise valueA$25,587 millionA$24,504 million

Equity valueA$18,450 millionA$18,528 million

Equity value(Infratil share)A$9,168 million (49.69%)A$9,213 million (49.72%)

Net debt

Including accrued Management Share payments

A$7,137 millionA$5,976 million

Key valuation assumptions

Risk free rate4.25%4.25%

Asset beta0.5750.575

Cost of equity (blended rate)

Reflects the assessed risk of the spectrum of CDC’s

portfolio, from operating data centres with contracted

revenues through to development projects without

contracted revenues.

12.58% (+0.13%)12.45%

Long term EBITDA margin83% (2055)83% (2055)

Capex

Valuation assumes no development beyond

2040

Valuation assumes no development beyond

2040

Independent Valuation Assumptions

2

460
550550

400

810810

1,740

2,580

2,820

0

1,000

2,000

3,000

4,000

Mar-26Jun-26Sep-26

CDC Capacity Pipeline (MW), rounded

1

OperatingUnder constructionFuture build

•Leasable operating and under construction capacity remained unchanged

this quarter as development continued across multiple sites.

•Australian future build capacity increased by 240MW to 2.7GW, reflecting

continued expansion of CDC’s longer-term pipeline to meet strong customer

demand.

•CDC is exploring a number of potentialprojects in Australia and New

Zealand which may be included in the pipeline in the future, subject to

progress against project milestones.

CDC Development Pipeline

Notes: (1) Leasable capacity to FY40, rounded to the nearest 10MW.

3

Leasable Capacity Pipeline

by Region, rounded

1

(MW)

September 2026June 2026

Operating capacity

ACT120120

NSW220220

VIC130130

NZ8080

Total550550

Under construction capacity

ACT--

NSW560560

VIC230230

Other AUS2020

NZ--

Total810810

Future build capacity

AUS2,7302,490

NZ9090

Total2,8202,580

Total Capacity Pipeline4,1803,940

2,600

3,9404,180

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • KFL — Kingfish Limited: KFL – November 2026 monthly update
    2026-11-16

    “1 A WORD FROM THE MANAGER The Kingfish portfolio gross performance return and adjusted NAV return in October were both -1.3%, versus the New Zealand shares benchmark S&P/NZX 50 return of -0.3%. Portfolio Auckland Airport (+1%) reiterated its earnings guidance for underlying…”

  • KFL — Kingfish Limited: KFL – August 2026 monthly update
    2026-08-16

    “1 A WORD FROM THE MANAGER The Kingfish portfolio gross performance return and adjusted NAV return in July were +0.7% and +0.6% respectively, versus the New Zealand shares benchmark S&P/NZX 50 return of +0.6%. a2 Milk (-6%) provided an update which confirmed next month it will…”